

1 **Nε- and O-Acetylation in *Mycobacterium tuberculosis* Lineage 7 and Lineage 4 strains:**
2 **Proteins Involved in Bioenergetics, Virulence and Antimicrobial Resistance are**
3 **Acetylated**

4 Alemayehu Godana Birhanu^{1, 2*}, Solomon Abebe Yimer^{1, 3}, Carol Holm-Hansen⁴, Gunnstein
5 Norheim⁴, Abraham Aseffa⁵, Markos Abebe⁵, Tone Tønjum^{1, 3*}

6 ¹Department of Microbiology, University of Oslo, PO Box 4950, Nydalen, NO-0424 Oslo,
7 Norway

8 ²Addis Ababa University, Institute of Biotechnology, PO Box 1176, Addis Ababa, Ethiopia

9 ³Department of Microbiology, Oslo University Hospital, PO Box 4950, Nydalen, NO-0424
10 Oslo, Norway

11 ⁴Infection Control and Environmental Health, Norwegian Institute of Public Health, PO Box
12 4404, Nydalen, NO-0403 Oslo, Norway

13 ⁵Armauer Hansen Research Institute, Jimma Road, PO Box 1005, Addis Ababa, Ethiopia

14 Email address of all co-authors:

15 alexbiology97@yahoo.com
16 s.a.yimer@medisin.uio.no
17 carol.holm-hansen@fhi.no
18 gunnstein.norheim@fhi.no
19 aseffaa@gmail.com
20 markosabebe@yahoo.com
21 tone.tonjum@medisin.uio.no
22

23

24

25

26

27

28

29

30 **ABSTRACT**

31 Increasing evidence demonstrates that lysine acetylation is involved in *Mycobacterium*
32 *tuberculosis* (Mtb) virulence and pathogenesis. However, previous investigations in Mtb have
33 only monitored acetylation at lysine residues using selected reference strains. We analyzed the
34 global N ϵ - and O-acetylation of 3 Mtb isolates; 2 lineage 7 clinical isolates and the lineage 4
35 H37Rv reference strain. Quantitative acetylome analysis resulted in identification of 2490
36 class-I acetylation sites, among them 2349 O-acetylation and 141 N ϵ -acetylation sites, derived
37 from 953 unique proteins. Mtb O-acetylation was thereby significantly more abundant than
38 N ϵ -acetylation. The acetylated proteins were found to be involved in central metabolism,
39 translation, stress responses and antimicrobial drug resistance. Notably, 261 acetylation sites
40 on 165 proteins were differentially regulated between lineage 7 and lineage 4 strains. A total
41 of 257 acetylation sites on 160 proteins were hypoacetylated in lineage 7 strains. These
42 proteins are involved in Mtb growth, virulence, bioenergetics, host-pathogen interaction and
43 stress responses. This study provides the first global analysis of O-acetylated proteins in Mtb.
44 This quantitative acetylome data expand the current understanding regarding the nature and
45 diversity of acetylated proteins in Mtb, and opens a new avenue of research for exploring the
46 role of protein acetylation in Mtb physiology.

47

48 **Keywords:** *Mycobacterium tuberculosis*; lineage 7; post-translational modifications;
49 *acetylome*; N ϵ -acetylation; O-acetylation.

50

51

52

53

54

55 INTRODUCTION

56 *Mycobacterium tuberculosis* (Mtb) is the causative agent of tuberculosis (TB) in humans.
57 TB is one of the top ten causes of mortality worldwide and the leading cause of deaths from
58 an infectious disease, leading to 1.8 million deaths and 10.4 million new cases in 2015 ¹. Due
59 to the increasing prevalence of antimicrobial drug resistance (AMR) and challenges in
60 vaccine development, it is crucial to understand fundamental aspects of Mtb biology to
61 achieve future elimination of this disease.

62 N ϵ -acetylation, which is acetylation at the ϵ -amine of lysine (K) residues, is an abundant
63 and evolutionarily conserved post-translational modification (PTM) that regulates a broad
64 range of functions in bacteria, including motility and chemotaxis, transcription, metabolism,
65 DNA metabolism, siderophore biosynthesis, and stress responses ²⁻⁵. Increasing evidence
66 supports the presence and role of lysine acetylation in mycobacteria ⁶⁻¹². In Mtb, lysine
67 acetylation presumably confers protein stability and compartmentalization, thereby
68 modulating diverse cellular processes ¹³⁻¹⁵. Acetylation of Mtb histone-like nucleoid protein
69 MthU modulates DNA binding and genome organization ¹⁶. It has also been shown that
70 reversible lysine acetylation regulates fatty acid metabolism in Mtb, and acetate and
71 propionate metabolism in *M. smegmatis* (Msm) ^{6,8}. Furthermore, Liu *et al.* have demonstrated
72 the regulatory role of lysine acetylation in the immunogenicity of the secreted protein HspX
73 in Mtb ¹⁷.

74 Lysine acetylation is modulated via both enzymatic and non-enzymatic mechanisms
75 (reviewed in ⁵). The enzymatic mechanism is regulated by the opposing actions of
76 acetyltransferases and deacetylases. Transfer of an acetyl group from acetyl-CoA (AcCoA) to
77 an N ϵ -lysine has been thought to occur enzymatically through lysine acetyltransferases,
78 generating acetylated K. Although a plethora of Mtb acetyltransferases and deacetylases are
79 predicted to be encoded by the Mtb genome ¹⁸, only a few of them are characterized to date.

80 Recently, Lee *et al.* assigned acetyltransferase activity to the Mtb Rv2170 protein that
81 acetylates lysine residues in isocitrate dehydrogenase, leading to a reduction in its enzymatic
82 activity¹⁹. Other characterized K acetyltransferases in Mtb includes Rv0998 and Rv3423.1,
83 which acetylate different target proteins^{10,20}. However, studies have demonstrated that lysine
84 acetylation can also occur non-enzymatically in bacteria and mitochondria, with the
85 secondary metabolite acetyl-phosphate (AcP) and AcCoA serving as the acetyl group donor
86²¹⁻²⁴. Non-enzymatic acetylation has been shown to occur via direct interaction of the target
87 protein and AcCoA, which is favored by high pH and high AcCoA concentrations such as
88 those in mitochondria²⁵⁻²⁶. Protein deacetylases in Mtb includes Rv1151c, the Mtb
89 homologue of cobB, which has been shown to deacetylate and regulate the activity of Mtb
90 acetyl-CoA synthase (ACS)^{2,7,17}. Deletion of deacetylases affects Mtb colony morphology
91 and biofilm formation, as well as stress responses¹⁷.

92 Mukherjee *at al.* discovered that YopJ, a secreted virulence factor from *Yersinia pestis*,
93 acetylates and inhibits kinase activation in the host by blocking phosphorylation²⁷. This is the
94 first report regarding the presence and function of O-acetylation, which is acetylation at the –
95 OH group of serine (S) and threonine (T) by a bacterial acetyltransferase. The function of
96 YopJ within *Y. pestis* itself is not known. However, there is no YopJ ortholog in Mtb. Protein
97 acetylation by itself is known to have a regulatory effect. Current evidence suggests that O-
98 acetylation becomes more important when acetylation takes place on kinase substrates, which
99 is known to regulate myriads of signaling pathways in Mtb²⁸⁻²⁹. The transfer of an acetyl
100 group to the –OH group of serine³⁰ and glycoconjugates (peptidoglycans)³¹⁻³² has also been
101 reported.

102 Despite phenotypic variability between strains of Mtb, most of the PTM studies
103 performed to date have used the reference laboratory strain H37Rv as a model organism^{15,17},
104³³. Furthermore, bacterial acetylome studies have been limited to the analysis of lysine

105 residues. O-acetylation of proteins has been shown to be involved in regulating key functions
106 in eukaryotes²⁷. The delineation of such regulatory mechanisms will not only lead to a better
107 understanding of Mtb basic biology and the discovery of potential new drug targets, but may
108 also facilitate the development of new vaccines and diagnostic tools.

109 In this study, we analysed the global N_e- and O-acetylome of two Mtb lineage 7
110 clinical isolates and the lineage 4 reference strain H37Rv using nanoscale liquid
111 chromatography coupled to tandem mass spectrometry (nano LC-MS / MS). The aim of this
112 study is to define the global N_e- and O-acetylome profile of Mtb and to predict its possible
113 contribution to the fitness and survival of Mtb using lineage 7 and lineage 4 strains as relevant
114 model organisms.

115 **EXPERIMENTAL PROCEDURES**

116 **Mycobacterial Strains and Growth Conditions**

117 Mtb lineage 7 strains (L7-35 and L7-28) and lineage 4 reference strain (H37Rv), were
118 inoculated onto Middlebrook 7H10 plates in triplicates and incubated in a humidified 37 °C,
119 5% CO₂ incubator. After 32 days, the cells were harvested and transferred to 50 mL Falcon®
120 tubes. The cell pellets were resuspended in 30 mL Phosphate-buffered saline (PBS)
121 containing, 10 mM PO₄³⁻, 137 mM NaCl, and 2.7 mM KCl, pH 7.4, and centrifuged at 3900
122 rpm for 20 min at 4 °C. The cell pellets were resuspended in 1 mL PBS, transferred into 2 mL
123 screw capped tubes (Sarstedt, Nümbrecht, Germany) and heat-inactivated at 80 °C for 90 min.
124 Culturing and processing of the Mtb samples prior to heat-inactivation were conducted in a
125 biosafety level 3 facility at Oslo University Hospital, Norway. The heat-inactivated Mtb
126 samples were stored at -20 °C until preparation for MS analysis.

127 **Preparation of Mtb Cell Lysate**

128 The inactivated cell pellets in lysis buffer containing 2% SDS, 10mM Tris-HCl (pH
129 7.5), 10 mM DTT, EDTA free protease inhibitor cocktail (Roche) and PhosStop (Roche),

130 were transferred into Lysing Matrix B tubes (Roche, US) and disrupted mechanically by bead
131 beating with MagNa Lyser for 90 seconds, speed 6.0 (Roche, US). The lysis procedure was
132 repeated six times with 1 min cooling on ice between each bead beating. The lysate was
133 clarified by centrifugation ($15,000 \times g$ for 15 min) at 21 °C, and the supernatant containing
134 the whole cell lysate proteins was transferred in to new 2 mL screw capped micro tubes
135 (Sarstedt, Germany). Protein concentration was measured by direct detect infrared
136 spectrometer (DirectDetect, Millipore).

137 **In-gel Trypsin Digestion**

138 One hundred μ g of protein dissolved in NuPAGE LDS sample buffer (1x) and
139 NuPAGE Sample Reducing Agent (1X) (Life Technologies) was incubated for 10 min at 70
140 °C and pre-fractionated by 1.0 mm, 4%-12% NuPAGE Novex Bis-Tris gel (Life
141 Technologies), at 80 V for 5 min followed by 20 min at 200 V. SDS-PAGE gels were
142 Coomassie stained using a Colloidal Blue Staining kit for NuPAGE according to the
143 manufacturer's instructions. After staining, each gel lane was divided into 6 fractions, and
144 each fraction was subjected to in-gel reduction, alkylation, and tryptic digestion³⁴. Proteins
145 were reduced using 10 mM DTT for 1 hour at 56 °C and alkylated with 55 mM
146 iodoacetamide for 1 hour at room temperature. The reduced and alkylated peptides were
147 digested with sequence grade trypsin (Promega, 1:100; w/w) for 16 hours at 37 °C in 50 mM
148 NH_4HCO_3 . The trypsin digested protein samples were extracted from the gel using
149 acetonitrile (ACN) (50% and 100%), dried by SpeedVac concentrator (Eppendorf,
150 concentrator 5301) and re-suspended using 0.05% trifluoroacetic acid (TFA). The digested
151 protein samples were loaded on to C18 zip-tips activated and equilibrated with 95%
152 ACN/0.1% FA and 0.1 % formic acid (FA), respectively. The loaded samples were washed
153 with 0.05% TFA and eluted with 95% ACN/0.1% FA. The eluent was dried using SpeedVac

154 concentrator, re-suspended in 0.1% FA, transferred to auto-sampler nano LC vials for LC-
155 MS/MS analysis and stored at -20 °C until injected in to LC-MS/MS.

156 **LC-MS/MS Analysis**

157 Peptide characterization and quantitation were performed by nano LC-MS / MS using
158 a Q Exactive hybrid quadrupole-orbitrap mass spectrometer interfaced with an EASY1000-
159 nano-electrospray ion source (both from Thermo Scientific).

160 Peptides were injected in triplicates on to a pre-column (Acclaim PepMap 100, 75 µm
161 x 2 cm, nanoviper, C18, 3 µm, 100Å, Thermo Scientific) and separated on an analytical
162 column (PepMap RSLC, C18, 2µm, 100Å, 50µm x 15cm, Thermo Scientific) at 75 min
163 solvent gradient and flow rate of 0.3 µl/min. Gradients from 2% to 30% solvent B for 30 min
164 followed by 30% to 75% solvent B from 30 to 35 min and 75% to 90% solvent B from 35 to
165 70 min were used. Thereafter, the gradient was kept at 90% solvent B from 70 to 75 min,
166 using 0.1% FA in 3% ACN as solvent A and 0.1% FA in 97% ACN as solvent B (FA: LC-
167 MS grade, Fluka; ACN: LC-MS grade, Merck). The column was operated at 60 °C. The mass
168 spectrometer was operated in data-dependent acquisition mode with automatic switching
169 between MS and MS/MS scans.

170 The full MS scans were acquired at 70K resolution, with automatic gain control target
171 of 1×10^6 ions, maximum injection time of 200 ms and the scan range was 300-1800 m/z for
172 MS scans. Higher energy collision dissociation (HCD) was used for peptide fragmentation
173 with normalized collision energy set to 28. The MS/MS scans were performed using a data-
174 dependent top10 method at a resolution of 17.5K with an automatic gain control target of $5 \times$
175 10^4 ions at maximum injection time of 100 ms and isolation window of 2.0 m/z units. An
176 underfill ratio of 10% and dynamic exclusion duration of 30 s was applied.

177 **Protein and PTM identification**

178 Protein and PTM site identification from the raw MS data was performed by using the
179 MaxQuant software with an integrated Andromeda search engine (version 1.5.7.4)³⁵⁻³⁶. The
180 raw mass spectral data were searched against the Uniprot Mtb protein database (downloaded
181 from <http://www.uniprot.org/> on Jan 15, 2017, uniprot ID: UP000001584,
182 Organism/Taxonomy ID: 83332 and with 3993 protein sequences) concatenated to reverse
183 decoy database and protein sequences for common contaminants.

184 Trypsin/P was specified as a cleavage enzyme allowing up to two missed cleavages.
185 The “re-quantify” and “match between runs” options were utilized with a retention time
186 alignment window of 3 min. Dependent peptide search, second peptide, LFQ and iBAQ
187 were enabled. Carbamidomethylation on cysteine was set as the fixed modification and
188 acetylation on protein N-terminal, conversion of N-terminal glutamine and glutamic acid to
189 pyroglutamic acid and oxidation on methionine were set as the variable modifications. For the
190 PTM analysis, acetyl (KSTY) was set as the variable modification. Unique and razor
191 peptides were used for the quantification of modified peptides (PTM abundance).

192 Only peptides with a minimum length of seven amino acids and detected in at least
193 one or more of the replicates were considered for identification. For protein identification, a
194 minimum of two peptides, of which at least one was unique, was required per protein group.
195 The threshold of protein identifications were determined by false discovery rate (FDR) of
196 0.01. All other parameters in MaxQuant were set to default values.

197 All modified peptide spectra were validated by applying stringent site localization
198 probability of ≥ 0.75 and PEP of ≤ 0.01 prior to further analysis. PTM site identifications with
199 localization probability < 0.75 and PEP > 0.01 , protein groups with matches to proteins from
200 the reversed database, and contaminant protein sequences were removed from the analysis.
201 Modified peptides with quantifiable values in at least five of nine biological replicates in the

202 three strains were considered for label-free relative quantification. Acetylated peptide
203 intensities were used for quantification of PTM abundance.

204 **BIOINFORMATICS ANALYSIS**

205 **Statistical Analysis**

206 Bioinformatics analysis was performed using the Perseus software (version 1.5.6.0) as
207 previously described³⁷. The protein group output from MaxQuant was used as the basis for
208 all the subsequent statistical and Gene Ontology (GO) enrichment analysis. Following protein
209 identification by a MaxQuant database search, validation for multiple comparisons was
210 corrected using the Benjamini-Hochberg correction³⁸. For identification of significantly
211 changed acetylation sites between the two Mtb lineages, a two tailed unpaired student's T-test
212 with $FDR \leq 0.05$ and $S0=2$ was applied.

213 **GO and Pathway Enrichment Analysis of Acetylated Proteins**

214 The GO annotation of identified modified proteins was derived from the DAVID
215 Bioinformatics Resources 6.7 and Gene Ontology Consortium bioinformatics databases³⁹⁻⁴⁰.
216 The proteins were classified by GO annotation based on three terms; molecular function
217 (MF), biological process (BP) and cellular component (CC). Acetylated proteins were
218 classified based on their functional category using TubercuList Mtb database
219 (<http://tuberculist.epfl.ch/>)⁴¹⁻⁴². The Kyoto Encyclopedia of Genes and Genomes (KEGG)
220 was utilized to annotate the pathways⁴³. The enriched GO terms and KEGG pathways
221 provided corresponding information on p-value, count, percentage and fold enrichment. Any
222 pathway, biological process or molecular function with a p-value ≤ 0.05 was considered as
223 significantly enriched. The ScanProsite web-based tool (<http://prosite.expasy.org>) and
224 GenomeNet Database Resources (<http://www.genome.jp/tools/motif/>) were used to identify
225 PROSITE signature profiles and active site motifs that match the sequence of identified
226 acetylated peptides⁴⁴.

227 **PTM Motif Analysis**

228 Motif-X software version 1.2 ⁴⁵ (<http://motif-x.med.harvard.edu/motif-x.html>) was
229 used to analyze the enrichment of amino acid sequence motifs at specific positions of acetyl-
230 31-mers (15 amino acids upstream and downstream of the site) in all peptide sequences. All
231 protein sequences in the database were used as the background database parameter and other
232 parameters were set at default.

233 **Protein-Protein Interaction Network Analysis**

234 Protein-protein interaction (PPI) networks were generated and analyzed using
235 STRING database version 10 (<http://string-db.org/>) ⁴⁶ with a high confidence threshold of 0.7.
236 Highly connected clusters were identified using MCODE plug-in toolkit and the interaction
237 network was visualized using the Cytoscape software (<http://www.cytoscape.org>) (version
238 3.5.0) ⁴⁷.

239 **Ethical Approval**

240 The study obtained ethical approval from the Regional Committee for Medical
241 Research Ethics in Eastern Norway (REK Øst) and Ethiopian Science and Technology
242 Ministry in Addis Ababa, Ethiopia. Sample collection was conducted after obtaining written
243 informed consent.

244 **RESULTS AND DISCUSSION**

245 **The First Combined N_ε- and O- Acetylome Map of Mtb**

246 In this study we analyzed the N_ε- and O-acetylome profile of two Mtb clinical isolates
247 from lineage 7 strain and the lineage 4 reference strain H37Rv. A total of 2490 class-I
248 acetylation sites, 2200 and 2198 acetylation sites in lineage 7 and lineage 4 ,
249 respectively(Figure 1A, 1B, Tables 1, SI 1, SI 2 and SI 3). These sites matched to 1568
250 proteins (953 unique proteins) (Table SI4). A representative spectra of two acetylated
251 peptides from heparin-binding hemagglutinin (HbhA) and conserved hypothetical protein

252 (Rv2020c) are shown in Figure SI 1 (Figure SI 1). Notably, 2310 (92.77%) of the totally
253 identified acetylome was shared between lineage 7 and H37Rv, highlighting the acetylome
254 conservation and consistency of the acetylome data (Figure 2A). Among the 953 unique
255 proteins, 44.28% of the proteins were singly acetylated while the remaining 55.82% of the
256 proteins were acetylated at two or more sites (Figure 2C). The most heavily acetylated
257 proteins included the 60 kDa chaperonin 2 GroEL2, mycolipanoate synthase Msl3, polyketide
258 synthase PKS13, ATP synthase subunit beta AtpD, chaperone protein DnaK and catalase-
259 peroxidase KatG (Figure 2C, Table SI 4). These heavily acetylated proteins are known to be
260 involved in stress responses, corroborating previous data indicating a role for protein
261 acetylation in stress adaptation in Mtb and other bacteria ^{17, 48-49}.

262 **O-Acetylation at Serine, Threonine or Tyrosine Represents 94.34 % of the Sites**
263 **Identified on 88.56 % of the Acetylated Proteins**

264 Out of a total of 2490 acetylation sites identified, 2349 sites on 844 proteins were
265 found to be O-acetylated. The abundance of acetylation was highest on T residues (39.32%),
266 followed by S (36.39%), Y (18.80%) and K residues (5.66%) (Figure 2B, Table 1). The
267 proportion of O-acetylated residues in Mtb is similar to the phosphorylation profile on the
268 three residues, S, T and Y ⁵⁰. The acetylated proteins identified accounted for 23.87% of the
269 total proteins annotated in Mtb, which may indicate that applying an enrichment-based
270 method would provide an even higher number of O-acetylated proteins than what has been
271 reported for the N_ε-acetylation ¹⁵.

272 N_ε-acetylation is the most commonly studied acetylation both in eukaryotes and
273 prokaryotes ⁴. A recent study on the Mtb acetylome, using an anti-acetyllysine antibody
274 enriched sample, reported a total of 1128 lysine acetylation sites on 658 proteins ¹⁵. Although
275 there is no former evidence for the presence of protein O-acetylation in prokaryotes, it is
276 known that O-acetylation is a common modification of bacterial peptidoglycan and other

277 glycoconjugates³¹⁻³². Serine O-acetyltransferase in plants and bacteria plays a role in the
 278 biosynthesis of cysteine from serine^{30, 51}. The O-acetyltransferase, N-hydroxyarylamine O-
 279 acetyltransferase (NhoA), has been shown to have an O-acetyltransferase activity in
 280 *Salmonella typhimurium*⁵². Based on the evidences discussed so far, including the YopJ O-
 281 acetyltransferase, we propose that the mechanism of O-acetylation and deacetylation on S, T
 282 and Y residues in Mtb probably follows a similar pattern as the N_ε-acetylation involving both
 283 enzymatic and non-enzymatic mechanisms and AcCoA as acetyl group donor. Further
 284 investigation is needed to elucidate the responsible mechanisms.




Figure 1 | (A) Overall difference and overlap in acetylated sites between *Mycobacterium tuberculosis* strains of lineage 7 and lineage 4 (H37Rv). (B) Overall difference and overlap in acetylated proteins between the four residues, S, T, Y and K. “n” in (A) and (B) stand for number of acetylation sites. (C) Distribution of acetylated proteins based on the number of acetylated sites per protein (Table SI 1,2,3).

Table 1 | Number of acetylation sites per residue in *Mycobacterium tuberculosis* proteins and the number and percentage of unique proteins acetylated.


Acetylated residues	Number of sites	Unique proteins	Percent (%)
Acetyl (Lysine, K)	141	109	5.66
Acetyl (Serine, S)	902	568	36.22
Acetyl (Threonine, T)	979	557	39.32
Acetyl (Tyrosine, Y)	468	334	18.80
Overall unique elements	2490	953	23.87

302

303 Bioinformatics analysis showed that these proteins share similar functions with N_ε-
304 acetylated proteins, as evident from previous reports on lysine acetylation^{15,17}. Even though
305 there was a relatively low coverage of acetylated proteins in this enrichment-free method, a
306 separate enrichment analysis for 109 lysine acetylated proteins and 840 exclusively O-
307 acetylated proteins provided a distinct profile of biological processes and KEGG pathways
308 associated to a particular acetylation. Exclusively O-acetylated proteins were involved in a
309 broad range of KEGG pathway and biological processes, including fatty acid and carbon
310 metabolism, translation, biosynthesis of secondary metabolites and antibiotics, amino acid
311 metabolism, glyoxylate and dicarboxylate metabolism and microbial metabolism in diverse
312 environments (Figure 2A). In contrast, proteins acetylated at K residues were found to be
313 involved in limited KEGG pathways and biological processes, primarily translation and the
314 citrate cycle (TCA cycle) (Figure 2B).

315 These data may indicate that the stoichiometry of O-acetylation is more plentiful than
316 N_ε-acetylation. This may support the assumption that O-acetylation is involved in regulating a
317 myriad of biological processes beyond that of N_ε-acetylation. Furthermore, the number of O-
318 acetylated peptides significantly outweighs the N_ε-acetylated peptides. These frequent
319 occurrences together with their competitive inhibition of phosphorylation may broaden the
320 role of O-acetylated proteins in regulating bacterial physiology^{49, 53}. Further enrichment-

321 dependent methods for each of the four residues is necessary to complete the catalogue of N_{ϵ} -
 322 and O-acetylated proteins and their respective enriched KEGG pathways.



336 **Figure 2 |** GO enrichment analysis for biological process and KEGG pathways in exclusively
 337 O-acetylated *Mycobacterium tuberculosis* proteins (A) and in N_{ϵ} -acetylated Mtb proteins (B).

338 **Acetylated Peptides were Identified Inside or Near PROSITE Signature Motifs**

339 MS-derived sequence windows data was used to search the PROSITE signature motifs,
 340 active sites, and domain profiles. Some of the acetylated peptides identified were found near
 341 or inside enzyme active site domains (Table SI 5-1, Table SI 5-2). The polar residues histidine,
 342 cysteine, aspartate, glutamate, arginine, lysine, tyrosine, serine, threonine, asparagine,
 343 glutamine and tryptophan are the most frequent catalytic amino acid residues⁵⁴⁻⁵⁵. S, T and Y
 344 are the major substrates for protein kinases that are hubs for complex regulatory networks,
 345 and are involved in blocking phagosome-lysosome fusion, the hallmark of Mtb pathogenesis
 (reviewed in²⁸⁻²⁹). The interplay between acetylation and phosphorylation of the same

346 residues may have implications in the fine-tuning of certain cellular processes including Mtb
347 pathogenesis. As a result, acetylation of major active site residues, including K, S, T and Y
348 may affect protein activity^{27, 56}.

349 Acetylation of K residues found within an enzyme active site neutralizes the positive
350 charge on lysine residues, which results in concomitant alteration in protein activity⁵⁷,
351 protein-protein and protein-DNA interactions⁵⁸⁻⁶⁰, local protein conformation⁶¹, and protein
352 localization⁶²⁻⁶³. Protein acetylation increases the net negative charge^{62, 64} on DNA binding
353 proteins that might inhibit their binding capacity of the positively charged lysine residues with
354 the negatively charged phosphate groups on DNA as reviewed by Carabetta *et al.*⁵. The
355 inhibitory effect of acetylation on K residues found in the active sites of enzymes ACS, NhoA,
356 adenosylmethionine synthase (MAT), and MbtA is highlighted in this review.


357 In our study we found that the pyruvate kinase active site signature (Pyk) was one of
358 the prosite motifs identified to be acetylated at position K221 (Table SI 5-2). The lysine
359 residue in the Pyk active site seems to be the acid/base catalyst responsible for the
360 interconversion of pyruvate and enolpyruvate. In accordance with our finding, mutagenesis of
361 the active site K221 of the pyruvate kinase was shown to reduce the activity of this enzyme
362 by a factor of 10⁴ to 10⁵ in *Bacillus stearothermophilus*⁶⁵. Even though the effect of O-
363 acetylation on bacterial enzyme activity has not been investigated to date, it is possible that
364 direct acetylation of such active site residues may modulate, abolish or induce the enzyme
365 activity⁴⁹ or interfere with the phosphorylation event⁵³.

366 **The Positively Charged Lysine and Arginine Residues are Enriched Towards the N-** 367 **Terminus of the Acetylation Sites**

368 It is highly likely that acetylation events follow conserved linear protein sequence
369 motifs similar to the motifs observed in protein phosphorylation. Two conserved putative

370 motifs were identified for acetylated peptides on K residues, namely RKac and R*Kac at
 371 different abundances (Figure 3A, 3B).

372 The acetylation motifs identified in both N_c- and O-acetylated residues were
 373 consistent, having the positively charged K and/or arginine (R) residues between -1 and -6
 374 positions to the N-terminus of the acetylated residues and L at -1 or -3 positions in some of
 375 the acetylated S and T residues (Figure 3A, 3B).



388 **Figure 3** | (A) *Mycobacterium tuberculosis* protein acetylation motifs and conservation of
 389 acetylation sites. (B) Number of identified peptides contained in each conserved motifs for the
 390 four residues.

390 Previous studies on lysine acylation showed that the positively charged K and R
 391 residues were significantly enriched residues at the C-terminus^{15, 66}, N- and C-terminus⁶⁷ and
 392 N-terminus⁴⁹ of the acylation sites. This variation may be attributed to the difference in the
 393 methods used in the different studies, for example in antibodies used for immunoaffinity
 394 enrichment⁵. These motifs may serve as a recognition signature for putative bacterial

395 acetyltransferases and deacetylases as observed in eukaryotes, or could be part of an
396 autocatalytic mechanism that facilitates the non-enzymatic acetylation process, thereby
397 regulating substrate specificity, enhancing acetyltransferase activity, and restricting access to
398 non-target proteins^{5, 68}.

399 **Acetylated Peptides Identified are Involved in Diverse Cellular Processes**

400 Among the 953 acetylated Mtb-proteins identified, 78.5% were annotated for KEGG
401 pathways, 92.0% for biological processes and 94.3% for molecular functions, while only 35.1%
402 were annotated for cellular components.

403 The predicted subcellular location of the acetylated proteins showed that most of the
404 acetylated proteins identified were related to the cytoplasm (60%), while a few proteins were
405 predicted to be membrane associated (20%), in macromolecular complexes (10%), associated
406 to organelles (8%), or located in the extracellular region (2%) (Figure 4A). The GO analysis
407 of biological processes and molecular functions shows that large numbers of acetylated
408 proteins are enzymes (73%) involved in metabolism (60%), respectively (Figure 4B, 4C).
409 Binding proteins are the second largest acetylated protein group in terms of molecular
410 function, accounting for 15% of the total number of acetylated proteins identified (Figure 4B).
411 Proteins associated with cellular processes represented the second largest protein group in
412 terms of biological process covering 24% of all annotated proteins (Figure 4C).

413 The acetylated proteins identified were grouped based on TubercuList functional
414 categories (<http://tuberculist.epfl.ch/>). The percentage was calculated by dividing the number
415 of acetylated proteins in each group by the total number proteins known to function in a
416 particular category (Figure 4D)⁴¹. Proteins involved in information pathways had the most
417 abundant acetylation (105/241, 43.57%), followed by proteins involved in lipid metabolism
418 (106/247, 42.91%) and intermediary metabolism and respiration (373/923, 40.41%).

419

420

421

422

423

424

425

426

427

428

429

430

431


432

433

434

435

436



437

438

439

Figure 4 | Gene Ontology functional classification of the *Mycobacterium tuberculosis* acetylated proteins identified. (A) Subcellular localization of the acetylated proteins. (B) Classification of the acetylated proteins based on molecular function. (C) Classification of the acetylated proteins based on biological process. (D) Percentage of acetylated proteins within their respective functional category.

440


441

442

443

The GO enrichment analysis and protein-protein interaction analysis (PPI) showed that proteins involved in translation and the structural constituents of ribosomes are the most abundant among the significantly enriched acetylated proteins in terms of biological processes and molecular function, respectively (Figure 5, Table SI 6-1, Figure SI 2). Despite the

444 variations in the methods used and the acetylated residues analysed, this finding was in
 445 agreement with a previous study on lysine acetylation and succinylation^{15, 17, 49}.



468 **Figure 5** | Gene Ontology enrichment analysis of identified acetylated *Mycobacterium tuberculosis* proteins based on molecular function, KEGG pathways and biological process.

469 It has been shown that lysine acetylation regulates cellular metabolism via different
470 mechanisms such as enzymatic activation or inhibition, and by influencing protein stability¹⁷,
471⁶⁹⁻⁷⁰. We identified eight acetylated enzymes involved in the TCA cycle^{69, 71} and two
472 enzymes, isocitrate lyase (ICL) and malate synthase G (GlcB), involved in the glyoxylate
473 pathway. Both copies of the ICL genes encoding AceaA and AceaB are essential for survival
474 of *Mtb in vivo*⁷²⁻⁷⁴. In *E. coli*, it has been shown that His356 is one of the catalytic active site
475 residues in ICL⁷⁵. Furthermore, Wang *et al.* have shown that acetylation of AceA with
476 protein acetyltransferase (Pat) or acetylation-mimicking mutations has led to reduction in
477 AceA activity and its activity was restored by deacetylation via CobB⁶⁹. We found that AceA
478 and Aceb were acetylated at 2 and 5 sites, respectively. AceAb was acetylated at S355, near
479 the catalytic residue H356, indicating that acetylation of this residue may lead to a
480 conformational change in the protein and therefore affect its enzymatic activity. GlcB is also a
481 virulence factor involved in *Mtb* adherence to lung epithelial cells⁷⁶

482 ACS is another acetylated protein involved in the synthesis of AcCoA, a key
483 intermediate in energy metabolism and an acetyl group donor in protein acetylation. ACS was
484 the first enzyme in *Mtb* shown to be regulated by reversible post-translational acetylation via
485 cAMP-dependent protein acetyltransferase¹¹⁻¹². The acetylation status of ACS determines the
486 activity that might influence the availability of the acetyl donor, AcCoA, and the metabolic
487 state of the cell⁷⁷.

488 The glyoxylate cycle is another pathway enriched by acetylated proteins. When the
489 TCA cycle is down-regulated upon oxygen and nutrient/glucose depletion, replenishment of
490 TCA cycle intermediates is achieved via the glyoxylate cycle using the AcCoA from fatty
491 acid β -oxidation as a carbon source for subsequent metabolic pathways in the synthesis of
492 biomolecules (glucose, amino acids, DNA, and RNA)⁷⁸⁻⁸⁰. Protein acetylation has been
493 shown to regulate the activity of enzymes controlling the direction of glycolysis versus

494 gluconeogenesis and the branching between TCA cycle and glyoxylate cycle by Pat and
495 deacetylase⁶⁹.

496 Fatty acid metabolism was one of the pathways identified by KEGG pathway
497 enrichment analysis in this study. In addition to being a source of AcCoA, fatty acids are an
498 integral component of the Mtb cell wall and known to be related to Mtb pathogenicity⁸¹. It
499 has been shown that reversible protein acetylation can regulate the activity of a number of
500 fatty-acid-CoA ligases in Mtb^{6,70}. These findings suggest that acetylation may play a role in
501 the regulation of various cellular processes in Mtb. Additional functional studies are needed to
502 validate these claims.

503 **Very few Mtb Proteins Involved in Genome Maintenance are Acetylated**

504 Most components involved in DNA repair, recombination and replication (3R
505 components) were not acetylated even though they are located in the cytosol among core
506 metabolic enzymes. The only 3R components found to be acetylated were DNA gyrases
507 TopA, GyrA and GyrB, single-stranded binding protein SSB, nucleotide excision repair DNA
508 damage sensor UvrA, and recombination factors RecB and RecF. Ku ligase and DnaA were
509 by Nε-lysine acetylation enrichment previously found to be acetylated in Msm and *E. coli*,
510 respectively⁸²⁻⁸³. Thus, along with all surface components, most 3R enzymes were found to
511 be constituents of the non-acetylated complement of Mtb cells (Table SI 4).

512 **Proteins involved in Antimicrobial Drug Resistance are Acetylated in Mtb**

513 Several bacterial species, including Mtb, alter their proteins involved in drug
514 resistance or drug targets, which in turn decreases or blocks the affinity for drug binding
515 without affecting normal activity⁴⁹. PTMs may alter the net charge on the protein,
516 conformation, interaction and activity, thereby modulating the bacterial response to drugs.
517 Acetylation of kinase substrates might alter the signaling pathways that lead to drug
518 resistance/sensitivity. Seven Mtb proteins associated with isoniazide (INH) resistance,

519 including KatG, InhA, NdhA KasA, AhpC, FadE24, and AcpM, were acetylated (Table SI 4)
520 ^{49, 84}. KatG, a catalase-peroxidase enzyme, is responsible for peroxidative activation of the
521 prodrug INH and acts as a virulence factor to protect against oxidative stress ⁸⁵. Mutations at
522 KatG positions S315T and R463L have been shown to diminish its capacity to activate INH
523 and confer INH resistance to Mtb ⁸⁶. An acylation study showed that succinylation of KatG at
524 K310 near the S315T mutation assists the enzyme in retaining its native antioxidant activity,
525 while the INH activating property was reduced by almost 30% and the minimum inhibitory
526 concentration of bacteria increased up to 200-fold ⁴⁹. Among the 8 differentially acetylated
527 sites on KatG, S465 was found near the natural mutation R463L. Acetylation of this residue
528 may lead to a conformational change in the protein and therefore affect its activity.

529 Serine/threonine protein kinases (STPKs) and two-component signal transduction
530 systems are key regulators of metabolic processes, including transcription, cell development,
531 stress response, virulence, host-pathogen interactions and drug resistance ⁸⁷⁻⁸⁸. Four of the
532 eleven Mtb STPKs, PknD, PknK, PknG and PknH, were acetylated at various residues. OpcA
533 and Wag31, have been shown to be up-regulated in INH-resistant Mtb strains ^{49, 89}; OpcA and
534 Wag31 are involved in peptidoglycan biosynthesis and oxidative stress responses ⁹⁰⁻⁹¹.
535 Another protein, PpiA, is involved in cationic antimicrobial peptide (CAMP) resistance ⁹².
536 MurF is a protein involved in cell wall synthesis and implicated in vancomycin resistance in
537 Mtb ⁹³. Thus, acetylation of a protein in an active site residue or anywhere in the protein
538 sequence may alter the protein function in various modes.

539 InhA, NADH-dependent enoyl-ACP reductase, is a major enzyme involved in the
540 biosynthesis of mycolic acids. Mutation at InhA I74T has been associated with resistance
541 to ethambutol (EMB), INH, rifampicin (RMP), and streptomycin (SM) ⁹⁴. We identified an
542 acetylation site on InhA at position T79 which is only five amino acids away from the natural


543 mutation I74T. Other acetylated proteins with a role in resistance to first-line anti-TB drugs
544 include RpoB, EmbR, PhoP, FabG1 and RpsL^{84,95}.

545 Mutations in the genes encoding DNA gyrase subunits, *gyrA* and *gyrB*, are the most
546 common mechanisms for acquiring fluoroquinolone (FQ) resistance in *Mtb*⁹⁶. The most
547 frequent FQ resistance-associated mutations, termed the quinolone resistance-determining
548 region, resides between codons 74 to 113 in *gyrA* and between 461 to 538 in *gyrB*⁹⁶⁻⁹⁸. We
549 found two acetylation sites at T500 and S473, which are located within the quinolone
550 resistance-determining region of GyrB, and may play a role in drug resistance, DNA
551 replication, and *Mtb* survival. Another acetylated proteins involved in drug resistance is
552 enhanced intracellular survival (Eis), an acetyltransferase, that confers resistance to
553 kanamycin by modifying the drug⁹⁹⁻¹⁰⁰.

554 **Proteins Associated to Virulence, Growth and Stress Responses are Differentially** 555 **Acetylated Between Lineage 7 and Lineage 4 Strains**

556 From a total of 2490 acetylation sites identified on 953 proteins, 1085 sites on 506
557 proteins were eligible for quantification. We found that 261 acetylation sites on 165 proteins
558 were differentially acetylated between lineage 7 and lineage 4 at $S_0=2$ and $FDR \leq 0.05$
559 (Figure 6A, 6B). Interestingly, 257 sites on 160 proteins involved in *Mtb* growth and
560 virulence were hypoacetylated in lineage 7 with fold changes between 4.2 and 628.4. Only
561 four sites on four proteins were significantly hyperacetylated in lineage 7 strains. Lineage 7 is
562 a recently identified lineage of *Mtb*, characterized by slow-growth and reduced virulence
563 phenotypes¹⁰¹⁻¹⁰². The GO enrichment analysis of 160 proteins hypoacetylated in lineage 7
564 revealed that pathogenesis, growth, glycolysis, response to iron ion, response to nitrosative
565 stress and protein folding were among the significantly enriched biological processes (Figure
566 7A, 7B). Carbon metabolism, TCA cycle, oxidative phosphorylation and microbial

567 metabolism in diverse environments were some of the significantly enriched pathways from
 568 these hypoacetylated proteins (Figure 7B, Table SI 6-2).



580 **Figure 6** | (A) Hierarchical clustering of differentially acetylated proteins between lineage 7
 581 and lineage 4 strains of *Mycobacterium tuberculosis* (Mtb). (B) Volcano plot of differentially
 582 acetylated proteins between lineage 7 and H37Rv (So=2, FDR \leq 0.05; -Log Student's T-test p-
 583 value in Y-axis and Student's T-test Difference in X-axis). Red: hyperacetylation and Green:
 584 hypoacetylation.

583 A number of enzymes involved in carbon metabolism, fatty acid metabolism, stress
 584 response, growth, virulence and the Esx-3 secretion system were hypoacetylated in lineage 7
 585 (Figure 7A, 7B, Table 2, Table SI 7). The dihydrolipoyllysine-residue acetyltransferase
 586 component of the pyruvate dehydrogenase complex (DlaT) and aconitate hydratase A (AcnA)
 587 are two proteins involved in the TCA cycle. Both enzymes were found to be hyperacetylated
 588 at lysine residues in lineage 4 strains. AcnA was acetylated at K273 position with fold change
 589 of 7.83, whereas DlaT was acetylated at two positions, K273 and K287, with fold changes of
 590 8.27 and 6.66, respectively. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and
 591 enolase (Eno) are two hypoacetylated enzymes involved in glycolytic pathway. Eno was

592 acetylated at 5 sites with fold changes between -8.14 to 15.59 , while GAPDH was acetylated
593 at position S259 with a fold change of 7.03 (Table 2, Table SI 7).

594 Energy metabolism is associated to growth and virulence in intracellular bacteria,
595 including Mtb¹⁰³⁻¹⁰⁴. Central carbon metabolism uses different carbon sources to generate the
596 building blocks, cofactors, and energy for cell growth. Wang *et al.* have shown that enzymes
597 involved in *Salmonella enterica* central carbon metabolism are regulated by reversible lysine
598 acetylation, involving protein acetyltransferase (Pat) and deacetylases (CobB)⁶⁹. In *S.*
599 *enterica*, acetylation of GAPDH has been shown to favor the glycolytic pathway while
600 inhibiting gluconeogenesis by more than 30% while deacetylation of GAPDH by the sirtuin
601 CobB stimulates gluconeogenesis and inhibits glycolytic pathway⁶⁹. Furthermore, it has been
602 shown that *S. enterica* deficient in *cobB* (with high acetylation) grew faster than the wild-type
603 cells in minimal glucose medium but grew slower than the wild type in minimal citrate
604 medium. This indicates the importance of protein acetylation in regulating bacterial growth⁶⁹.
605 The detailed mechanism of the regulation needs to be investigated. The activity of pyruvate
606 dehydrogenase, one of the hypoacetylated enzymes involved in the TCA cycle, is reduced by
607 lysine acetylation in eukaryotes¹⁰⁵⁻¹⁰⁶, and this might also be true in bacteria. ACS was found
608 to be hypoacetylated in lineage 7 strains with a fold change of 5.44. AcCoA is the substrate
609 for the glyoxylate cycle¹⁰⁷. The glyoxylate cycle has been shown to be up-regulated during
610 Mtb growth arrest and involved in Mtb persistence¹⁰⁸⁻¹⁰⁹. Moreover, previous works indicated
611 the possible role of ACS in controlling the expression and/or activity of the glyoxylate cycle
612 in *E. coli*¹¹⁰⁻¹¹¹. Therefore, the acetylation status of Mtb ACS might have a role in modulating
613 Mtb physiology and persistence^{11, 107}. Mtb utilizes lactate as a potential carbon and energy
614 source inside macrophages¹¹². L-lactate dehydrogenases (LldD), an enzyme involved in the
615 oxidation of lactate, was hypoacetylated in lineage 7 with fold change of -258.83.

616 AcCoA can be generated from different substrates, including glucose, fatty acids,
617 amino acids and citrate. Once generated, it is used in ATP synthesis via TCA cycle, synthesis
618 of fatty acids, amino acids and other metabolites (reviewed in ⁷⁷). In addition, AcCoA is an
619 acetyl group donor for protein acetylation. Thus, acetylation of enzymes involved in AcCoA
620 synthesis, ACS, may also modulate all the processes involving AcCoA. These processes also
621 consume AcCoA and thereby alter the availability of AcCoA in the cell and metabolic state of
622 the cell.

623 In addition to the enzymes involved in TCA and glyoxylate cycles, a number of long-
624 chain-fatty-acid-CoA ligases associated with fatty acid metabolism were hypoacetylated in
625 Mtb lineage 7 strains with fold changes ranging from 4.54 to 14.35 (Figure 7A, Table 2, Table
626 SI 5). Enzymes involved in fatty acid β -oxidation were hypoacetylated in lineage 7 (Tables 2
627 and SI 7). Fatty acid metabolism, both synthesis and catabolism, is an important cellular
628 process for Mtb fitness and survival. More importantly, fatty acids and their derivatives are an
629 integral component of the cell wall complex and implicated in Mtb pathogenicity, fitness and
630 survival ^{17, 81, 113}. Mtb utilizes fatty acids as principal source of energy during dormancy and
631 reactivation ^{104, 114}. Survival of Mtb inside the phagolysosome depends on the pathogen's
632 ability to synthesize virulence factors (proteins) and other biomolecules in a glucose-limited
633 stress environment ⁸⁰. Reversible acetylation has been shown to modulate the activity of
634 several fatty-acid-CoA ligases ⁷⁰. Polyketide synthase (PKS13) was hypoacetylated in lineage
635 7 at 6 sites with fold changes ranging from -3.89 to -5.98. PKS13 is an enzyme involved in
636 the final steps of mycolic acid biosynthesis. Mycolic acids are an integral component of Mtb
637 cell wall and known to be related to its pathogenicity ⁸¹.

638 ESX-3 secretion system components were found to be highly acetylated in H37Rv.
639 Esx-3 is implicated in essential physiologic processes and metal homeostasis and crucial for
640 Mtb growth *in vivo* and *in vitro* ¹¹⁵. The phosphate-binding protein PstS 1 is involved in

641 inorganic phosphate uptake and its disruption has been shown to be associated to decreased
 642 virulence and attenuated growth ¹¹⁶. PstS 1 was hypoacetylated at 6 sites in lineage 7 with
 643 fold changes between -388.45 and -27.53.

Table 2 | List of proteins hypoacetylated in *Mycobacterium tuberculosis* lineage 7 strains.

Protein name	Gene ID	Acetylation	Fold change
Alkyl hydroperoxide reductase AhpD	Rv2159c	T285	-628.43
Alkyl hydroperoxide reductase AhpD	Rv2159c	T57	-450.62
Phosphate-binding protein PstS 1	<i>pstS1</i>	S347	-388.45
Putative L-lactate dehydrogenase	<i>lldD</i>	Y55	-258.83
Alkyl hydroperoxide reductase AhpD	Rv2159c	T165	-246.35
Serine/threonine-protein kinase PknD	<i>pknD</i>	S2	-179.07
Catalase-peroxidase	<i>katG</i>	S465	-153.46
Phosphate-binding protein PstS 1	<i>pstS1</i>	S186	-130.58
Alkyl hydroperoxide reductase AhpD	Rv2159c	S302	-89.98
Phosphate-binding protein PstS 1	<i>pstS1</i>	T160	-78.49
Phosphate-binding protein PstS 1	<i>pstS1</i>	S365	-68.62
ESX-3 secretion system protein EccA3	<i>eccA3</i>	S533	-49.83
ESAT-6-like protein EsxO	<i>esxO</i>	T2	-46.69
ESX-3 secretion system protein EccC3	<i>eccC3</i>	T891	-45.42
Isoniazid-induced protein IniB	<i>iniB</i>	S20	-42.15
Mycolipanoate synthase	<i>msh3</i>	Y1279	-30.14
Phosphate-binding protein PstS 1	<i>pstS1</i>	T328	-28.94
Probable CDP-diacylglycerol pyrophosphatase	<i>cdh</i>	Y84	-28.23
Phosphate-binding protein PstS 1	<i>pstS1</i>	K324	-27.53
Chaperone protein DnaK	<i>dnaK</i>	Y106	-24.68
Nitrate reductase alpha subunit	<i>narG</i>	T2	-23.58
Ferritin BfrB	<i>bfrB</i>	Y49	-18.81
Probable thiol peroxidase	<i>tpx</i>	T13	-18.61
Cytochrome BD ubiquinol oxidase subunit I	<i>cydA</i>	S307	-18.27
ESAT-6-like protein EsxO	<i>esxO</i>	Y65	-18.09
Alpha-crystallin	<i>hspX</i>	T101	-18.03
ESX-3 secretion system protein EccC3	<i>eccC3</i>	T726	-17.80
Mycolipanoate synthase	<i>msh3</i>	S2016	-16.50
ESX-3 secretion system protein EccC3	<i>eccC3</i>	T176	-16.15
Enolase	<i>eno</i>	K335	-15.59
ESX-3 secretion system protein EccA3	<i>eccA3</i>	T433	-15.40
Mycolipanoate synthase	<i>msh3</i>	T1259	-14.74
ESX-3 secretion system protein EccC3	<i>eccC3</i>	S125	-14.54
Long-chain-fatty-acid--CoA ligase FadD15	<i>fadD15</i>	T160	-14.35
Enolase	<i>eno</i>	S39	-14.15
Probable thiol peroxidase	<i>tpx</i>	T98	-13.50
Enolase	<i>eno</i>	S198	-13.30
Alpha-crystallin	<i>hspX</i>	S91	-13.27

644 Other groups of differentially acetylated proteins involved in stress response, virulence
 645 and pathogenesis includes chaperon proteins (DnaK, HspX), oxidoreductases (AhpD, Tpx and

646 KatG), ESX-1 secretion-associated proteins (EsxB, EspI, EspR and EspF), mammalian cell
647 entry proteins (Mce1B, Mce1F and Mce1C) and STPKs (PknD and PknH), drug resistance-
648 associated proteins (RpoB, RpoC and IniB) (Table 2, Table SI 7). These proteins are
649 indispensable for Mtb in signal transduction mechanisms that lead to bacterial adaptation to
650 its environment ⁸⁸, detoxification and drug resistance ^{86,117}, or involved in entry and survival
651 of the pathogen inside macrophages ¹¹⁸. Although the exact mechanism remains unknown,
652 acetylation of enzymes involved in Mtb fitness and survival may lead to a change in the net
653 charge of the protein, alter stability and compartmentalization, brings a conformational
654 change and/or block kinase substrates and may thus modulate activity.

655 The protein-protein interaction (PPI) network was established to investigate the
656 physical and functional interactions among the 261 differentially acetylated proteins. Eight
657 interconnected protein clusters were identified using the MCODE plug-in toolkit, and the PPI
658 network was visualized using the Cytoscape software. The clusters include proteins involved
659 in ESX-3 secretion (cluster 1), host-pathogen interactions (cluster 2), glycolysis (cluster 3),
660 TCA cycle (cluster 4), fatty acid metabolism (cluster 5), stress response (cluster 6),
661 transcription and translation (cluster 7) and ATP synthase (cluster 8) (Figure 7A).

662

663

664

665

666


667

668

669

670

671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693



694 **Figure 7** | (A) Protein-protein interaction network of differentially acetylated protein groups involved in; 1: ESX-3 secretion, 2: host-pathogen interaction, 3: glycolysis, 4: TCA cycle, 5: fatty acid metabolism, 6: stress response, 7: transcription and translation and, 8: ATP synthase. (B) GO enrichment analysis of proteins hypoacetylated in lineage 7.

695 A total of 71 acetylated sites on 69 proteins and 109 acetylated sites on 93 proteins
696 were exclusively identified in Mtb lineage 7 and lineage 4, respectively. GO enrichment
697 analysis of the exclusively identified acetylated proteins showed a strain-specific enrichment
698 of biological processes. Carbon and fatty acid metabolism were enriched in lineage 7 (Figure
699 SI 3), while translation and amino acid metabolism were enriched in lineage 4 (H37Rv)
700 (Figure SI 3). Enrichment of carbon and fatty acid metabolism in proteins exclusively
701 identified in lineage 7 might be considered as a compensatory mechanism for energy
702 generation.

703 CONCLUSIONS

704 This study generated the first extensive data on O-acetylation in Mtb. We identified a total
705 of 2490 acetylation sites on 953 Mtb unique proteins involved in a wide variety of
706 fundamental cellular processes. These acetylated proteins are involved in Mtb core metabolic
707 processes, bioenergetics, virulence and drug resistance. Our findings provide novel insight
708 into a range of functions predicted to be regulated by N_ε-and O-acetylation in Mtb. The
709 stoichiometry of Mtb O-acetylation is significantly higher than that of N_ε-acetylation. This
710 fact may in turn support the assumption that O-acetylation is involved in a broader range of
711 processes than the N_ε-acetylated counterparts. Due to the limited number of functional studies
712 on the impact of acetylation conducted to date, the contribution of lysine acetylation in Mtb
713 drug resistance is not fully understood. This study provides new knowledge on acetylated
714 proteins and acetylation sites found near naturally occurring mutations that are known to be
715 involved in Mtb drug resistance, and may be used as a basis for further functional studies.
716 Differentially acetylated proteins involved in Mtb virulence, energy metabolism/growth and
717 stress responses were uniformly biased towards being hypoacetylated in lineage 7 strains.
718 This may lead to a metabolic state that makes one strain better fitted to a certain environment

719 compared to the other. The real impact (inhibition/activation) of acetylation on protein
720 activity needs to be further investigated through functional studies.

721 This MS-based prediction focusing on the nature and role of protein acetylation in Mtb
722 should be verified by using both *in vivo* and *in vitro* functional studies, which can provide the
723 proof of concept for the role of acetylation in Mtb physiology. This investigation relied on
724 two methods, deletion of acetyltransferases/deacetylases and substitution. Deletion of either
725 the acetyltransferases or deacetylases can be used to unveil the role of these enzymes in the
726 acetylation process, while point mutations are used to assess the functional role of a specific
727 acetylation site. Finally, the use of immunoaffinity-enriched samples for nanoLC-MS/MS
728 analysis may enable the identification of large numbers of acetylated proteins to establish the
729 complete Mtb O-acetylome.

730 ASSOCIATED CONTENT

731 Supporting Information

- 732 • Figure SI 1. Representative spectra of N_ε- and O-acetylated peptides in Mtb (PDF).
- 733 • Figure SI 2. Protein-Protein interaction network analysis of N_ε- and O-acetylated
734 proteins in Mtb (PDF).
- 735 • Figure SI 3. GO Enrichment analysis of acetylated proteins exclusively identified in
736 Mycobacterium tuberculosis strains of lineage 7 (A) and lineage 4 (B) (PDF).
- 737 • Table SI 1. List of class-I acetylation sites (n=2198) identified in H37Rv; localization
738 probability >0.75 and PEF <0.05 (xlsx).
- 739 • Table SI 2. List of class-I acetylation sites (n=2200) identified in Lineage 7;
740 localization probability >0.75 and PEF<0.05 (xlsx).
- 741 • Table SI 3. List of total identified class-I acetylation sites (n=2490); localization
742 probability >0.75 and PEF<0.05 (xlsx).

- 743 • Table SI 4. List of 953 identified acetylated proteins and number of acetylation sites
744 per protein (xlsx).
- 745 • Table SI 5-1. PROSITE patterns of acetylated proteins. In red the PROSITE
746 signature, in green the identified acetylated site in *M. tuberculosis*, and the identified
747 peptides are between brackets (xlsx).
- 748 • Table SI 5-2. List of identified PROSITE profiles of acetylated peptides (xlsx).
- 749 • Table SI 6-1. Gene Ontology enrichment analysis for Nε- and O-acetylated proteins
750 using DAVID classification system, P-value < 0.05 (xlsx).
- 751 • Table SI 6-2. Gene Ontology enrichment analysis for differentially acetylated proteins
752 between lineage 7 and lineage 4 (H37Rv) using DAVID classification system (xlsx).
- 753 • Table SI 7. List of differentially acetylated proteins (n=261) in lineage 7 versus lineage
754 4 (xlsx).

755 AUTHOR INFORMATION

756 *Corresponding Author

757 Alemayehu Godana Birhanu

758 E-mail: alexbiology97@yahoo.com. Tel: (+47) 94294333.

759 **ORCID ID:** 0000-0001-5302-0919

760 Tone Tønjum

761 E-mail: tone.tonjum@medisin.uio.no. Tel: (+47) 90152936.

762 **ORCID ID:** 0000-0002-1709-6921

763 Author Contributions

764 TT, AGB, and SAY conceived the study and study design. SAY collected the lineage 7
765 isolates. AGB performed the MS sample preparation. AGB performed bioinformatics and
766 statistical analyses. AGB and TT evaluated and interpreted the data and drafted the paper. All
767 authors edited and approved the final manuscript.

768 **Notes**

769 The authors declare no competing financial interest.

770 The mass spectrometry proteomics data have been deposited to the ProteomeXchange

771 Consortium via the PRIDE ¹¹⁹ partner repository with the dataset identifier PXD006630.

772 **FUNDING**

773 Funding was received from the Research Council of Norway (RCN) FRIMEDBIO project #

774 204747 and RCN GLOBVAC projects #234506 to TT and 192468 to CH, and Norwegian

775 South-Eastern Health Authority project 2013080 to SAY and TT.

776 **ACKNOWLEDGMENTS**

777 We thank Tahira Riaz for acquiring the MS data. We also thank the patients for consenting to

778 participate in the study and selected health care facilities in the Amhara Region, Ethiopia, for

779 facilitating the study. We are grateful to the Armauer Hansen Research Institute (AHRI),

780 Addis Ababa, Ethiopia, and the Norwegian Institute of Public Health for facilitating the

781 transfer of lineage 7 strains for WGS at Oslo University Hospital.

782 **ABBREVIATIONS**

783 Mtb, *Mycobacterium tuberculosis*; PTM, post-translational modification; MS, mass

784 spectrometry; GO, Gene Ontology; FDR, false discovery rate; PEP, posterior error

785 probability; KEGG, Kyoto Encyclopedia of Genes and Genomes.

786 **REFERENCES**

787 1. WHO *Global Tuberculosis Report 2016*. World Health Organization, Geneva; 2016.
788 http://www.who.int/tb/publications/global_report/en/. (accessed May 15, 2017).

789 2. Cain, J. A.; Solis, N.; Cordwell, S. J., Beyond gene expression: the impact of protein
790 post-translational modifications in bacteria. *J Proteomics* **2014**, *97*, 265-86.

791 3. Vergnolle, O.; Xu, H.; Tufariello, J. M.; Favrot, L.; Malek, A. A.; Jacobs, W. R., Jr.;
792 Blanchard, J. S., Post-translational Acetylation of MbtA Modulates Mycobacterial
793 Siderophore Biosynthesis. *J Biol Chem* **2016**, *291* (42), 22315-22326.

794 4. Ouidir, T.; Kentache, T.; Hardouin, J., Protein lysine acetylation in bacteria: Current
795 state of the art. *Proteomics* **2016**, *16* (2), 301-9.

796 5. Carabetta, V. J.; Cristea, I. M., The regulation, function, and detection of protein
797 acetylation in bacteria. *J Bacteriol* **2017**, JB. 00107-17.

- 798 6. Nambi, S.; Gupta, K.; Bhattacharyya, M.; Ramakrishnan, P.; Ravikumar, V.; Siddiqui,
799 N.; Thomas, A. T.; Visweswariah, S. S., Cyclic AMP-dependent protein lysine acylation in
800 mycobacteria regulates fatty acid and propionate metabolism. *J Biol Chem* **2013**, *288* (20),
801 14114-24.
- 802 7. Gu, J.; Deng, J. Y.; Li, R.; Wei, H.; Zhang, Z.; Zhou, Y.; Zhang, Y.; Zhang, X. E.,
803 Cloning and characterization of NAD-dependent protein deacetylase (Rv1151c) from
804 *Mycobacterium tuberculosis*. *Biochemistry (Mosc)* **2009**, *74* (7), 743-8.
- 805 8. Hayden, J. D.; Brown, L. R.; Gunawardena, H. P.; Perkowski, E. F.; Chen, X.;
806 Braunstein, M., Reversible acetylation regulates acetate and propionate metabolism in
807 *Mycobacterium smegmatis*. *Microbiology* **2013**, *159* (Pt 9), 1986-99.
- 808 9. Lee, H. J.; Lang, P. T.; Fortune, S. M.; Sasseti, C. M.; Alber, T., Cyclic AMP
809 regulation of protein lysine acetylation in *Mycobacterium tuberculosis*. *Nat Struct Mol Biol*
810 **2012**, *19* (8), 811-8.
- 811 10. Nambi, S.; Basu, N.; Visweswariah, S. S., cAMP-regulated protein lysine acetylases in
812 mycobacteria. *J Biol Chem* **2010**, *285* (32), 24313-23.
- 813 11. Xu, H.; Hegde, S. S.; Blanchard, J. S., Reversible Acetylation and Inactivation of
814 *Mycobacterium tuberculosis* Acetyl-CoA Synthetase Is Dependent on cAMP. *Biochemistry*
815 **2011**, *50* (26), 5883-5892.
- 816 12. Li, R.; Gu, J.; Chen, P.; Zhang, Z.; Deng, J.; Zhang, X., Purification and
817 characterization of the acetyl-CoA synthetase from *Mycobacterium tuberculosis*. *Acta*
818 *Biochim Biophys Sin* **2011**, *43* (11), 891-899.
- 819 13. van Els, C. A.; Corbiere, V.; Smits, K.; van Gaans-van den Brink, J. A.; Poelen, M. C.;
820 Mascart, F.; Meiring, H. D.; Loch, C., Toward Understanding the Essence of Post-
821 Translational Modifications for the *Mycobacterium tuberculosis* Immunoproteome. *Front*
822 *Immunol* **2014**, *5*, 361.
- 823 14. Okkels, L. M.; Müller, E. C.; Schmid, M.; Rosenkrands, I.; Kaufmann, S. H.;
824 Andersen, P.; Jungblut, P. R., CFP10 discriminates between nonacetylated and acetylated
825 ESAT - 6 of *Mycobacterium tuberculosis* by differential interaction. *Proteomics* **2004**, *4* (10),
826 2954-2960.
- 827 15. Xie, L.; Wang, X.; Zeng, J.; Zhou, M.; Duan, X.; Li, Q.; Zhang, Z.; Luo, H.; Pang, L.;
828 Li, W.; Liao, G.; Yu, X.; Li, Y.; Huang, H.; Xie, J., Proteome-wide lysine acetylation
829 profiling of the human pathogen *Mycobacterium tuberculosis*. *Int J Biochem Cell Biol* **2015**,
830 *59*, 193-202.
- 831 16. Ghosh, S.; Padmanabhan, B.; Anand, C.; Nagaraja, V., Lysine acetylation of the
832 *Mycobacterium tuberculosis* HU protein modulates its DNA binding and genome
833 organization. *Mol Microbiol* **2016**, *100* (4), 577-88.
- 834 17. Liu, F.; Yang, M.; Wang, X.; Yang, S.; Gu, J.; Zhou, J.; Zhang, X. E.; Deng, J.; Ge, F.,
835 Acetylome analysis reveals diverse functions of lysine acetylation in *Mycobacterium*
836 *tuberculosis*. *Mol Cell Proteomics* **2014**, *13* (12), 3352-66.
- 837 18. Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S.
838 V.; Eiglmeier, K.; Gas, S.; Barry, C. E., 3rd; Tekaia, F.; Badcock, K.; Basham, D.; Brown, D.;
839 Chillingworth, T.; Connor, R.; Davies, R.; Devlin, K.; Feltwell, T.; Gentles, S.; Hamlin, N.;
840 Holroyd, S.; Hornsby, T.; Jagels, K.; Krogh, A.; McLean, J.; Moule, S.; Murphy, L.; Oliver,
841 K.; Osborne, J.; Quail, M. A.; Rajandream, M. A.; Rogers, J.; Rutter, S.; Seeger, K.; Skelton,
842 J.; Squares, R.; Squares, S.; Sulston, J. E.; Taylor, K.; Whitehead, S.; Barrell, B. G.,
843 Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence.
844 *Nature* **1998**, *393* (6685), 537-44.
- 845 19. Lee, W.; VanderVen, B. C.; Walker, S.; Russell, D. G., Novel protein
846 acetyltransferase, Rv2170, modulates carbon and energy metabolism in *Mycobacterium*
847 *tuberculosis*. *Sci Rep* **2017**, *7* (1), 72.

- 848 20. Jose, L.; Ramachandran, R.; Bhagavat, R.; Gomez, R. L.; Chandran, A.;
849 Raghunandan, S.; Omkumar, R. V.; Chandra, N.; Mundayoor, S.; Kumar, R. A.,
850 Hypothetical protein Rv3423.1 of Mycobacterium tuberculosis is a histone acetyltransferase.
851 *Febs Journal* **2016**, 283 (2), 265-281.
- 852 21. Weinert, B. T.; Iesmantavicius, V.; Wagner, S. A.; Scholz, C.; Gummesson, B.; Beli,
853 P.; Nystrom, T.; Choudhary, C., Acetyl-Phosphate Is a Critical Determinant of Lysine
854 Acetylation in *E. coli*. *Molecular Cell* **2013**, 51 (2), 265-272.
- 855 22. Kuhn, M. L.; Zemaitaitis, B.; Hu, L. I.; Sahu, A.; Sorensen, D.; Minasov, G.; Lima, B.
856 P.; Scholle, M.; Mrksich, M.; Anderson, W. F.; Gibson, B. W.; Schilling, B.; Wolfe, A. J.,
857 Structural, kinetic and proteomic characterization of acetyl phosphate-dependent bacterial
858 protein acetylation. *PLoS One* **2014**, 9 (4), e94816.
- 859 23. Kosono, S.; Tamura, M.; Suzuki, S.; Kawamura, Y.; Yoshida, A.; Nishiyama, M.;
860 Yoshida, M., Changes in the Acetylome and Succinylome of *Bacillus subtilis* in Response to
861 Carbon Source. *PLoS One* **2015**, 10 (6), e0131169.
- 862 24. Paik, W. K.; Pearson, D.; Lee, H. W.; Kim, S., Nonenzymatic acetylation of histones
863 with acetyl-CoA. *Biochim Biophys Acta* **1970**, 213 (2), 513-22.
- 864 25. Wagner, G. R.; Payne, R. M., Widespread and enzyme-independent N ϵ -acetylation
865 and N ϵ -succinylation of proteins in the chemical conditions of the mitochondrial matrix.
866 *Journal of Biological Chemistry* **2013**, 288 (40), 29036-29045.
- 867 26. Baeza, J.; Smallegan, M. J.; Denu, J. M., Site-specific reactivity of nonenzymatic
868 lysine acetylation. *ACS Chem Biol* **2015**, 10 (1), 122-8.
- 869 27. Mukherjee, S.; Keitany, G.; Li, Y.; Wang, Y.; Ball, H. L.; Goldsmith, E. J.; Orth, K.,
870 *Yersinia YopJ* acetylates and inhibits kinase activation by blocking phosphorylation. *Science*
871 **2006**, 312 (5777), 1211-4.
- 872 28. Cousin, C.; Derouiche, A.; Shi, L.; Pagot, Y.; Poncet, S.; Mijakovic, I., Protein-
873 serine/threonine/tyrosine kinases in bacterial signaling and regulation. *FEMS Microbiol Lett*
874 **2013**, 346 (1), 11-9.
- 875 29. Chao, J.; Wong, D.; Zheng, X.; Poirier, V.; Bach, H.; Hmama, Z.; Av-Gay, Y., Protein
876 kinase and phosphatase signaling in *Mycobacterium tuberculosis* physiology and
877 pathogenesis. *Biochim Biophys Acta* **2010**, 1804 (3), 620-7.
- 878 30. Denk, D.; Bock, A., L-cysteine biosynthesis in *Escherichia coli*: nucleotide sequence
879 and expression of the serine acetyltransferase (*cysE*) gene from the wild-type and a cysteine-
880 excreting mutant. *J Gen Microbiol* **1987**, 133 (3), 515-25.
- 881 31. Anonsen, J. H.; Borud, B.; Vik, A.; Viburiene, R.; Koomey, M., Structural and genetic
882 analyses of glycan O-acetylation in a bacterial protein glycosylation system: evidence for
883 differential effects on glycan chain length. *Glycobiology* **2017**, 1-12.
- 884 32. Moynihan, P. J.; Clarke, A. J., O-Acetylated peptidoglycan: controlling the activity of
885 bacterial autolysins and lytic enzymes of innate immune systems. *Int J Biochem Cell Biol*
886 **2011**, 43 (12), 1655-9.
- 887 33. Yang, M.; Wang, Y.; Chen, Y.; Cheng, Z.; Gu, J.; Deng, J.; Bi, L.; Chen, C.; Mo, R.;
888 Wang, X.; Ge, F., Succinylome analysis reveals the involvement of lysine succinylation in
889 metabolism in pathogenic *Mycobacterium tuberculosis*. *Mol Cell Proteomics* **2015**, 14 (4),
890 796-811.
- 891 34. Shevchenko, A.; Tomas, H.; Havlis, J.; Olsen, J. V.; Mann, M., In-gel digestion for
892 mass spectrometric characterization of proteins and proteomes. *Nat Protoc* **2006**, 1 (6), 2856-
893 60.
- 894 35. Cox, J.; Mann, M., MaxQuant enables high peptide identification rates, individualized
895 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat Biotechnol* **2008**,
896 26 (12), 1367-72.

- 897 36. Cox, J.; Neuhauser, N.; Michalski, A.; Scheltema, R. A.; Olsen, J. V.; Mann, M.,
898 Andromeda: a peptide search engine integrated into the MaxQuant environment. *J Proteome*
899 *Res* **2011**, *10* (4), 1794-805.
- 900 37. Tyanova, S.; Temu, T.; Sinitcyn, P.; Carlson, A.; Hein, M. Y.; Geiger, T.; Mann, M.;
901 Cox, J., The Perseus computational platform for comprehensive analysis of (prote)omics data.
902 *Nat Methods* **2016**, *13* (9), 731-40.
- 903 38. Benjamini, Y.; Drai, D.; Elmer, G.; Kafkafi, N.; Golani, I., Controlling the false
904 discovery rate in behavior genetics research. *Behav Brain Res* **2001**, *125* (1-2), 279-84.
- 905 39. Ashburner, M.; Ball, C. A.; Blake, J. A.; Botstein, D.; Butler, H.; Cherry, J. M.; Davis,
906 A. P.; Dolinski, K.; Dwight, S. S.; Eppig, J. T.; Harris, M. A.; Hill, D. P.; Issel-Tarver, L.;
907 Kasarskis, A.; Lewis, S.; Matese, J. C.; Richardson, J. E.; Ringwald, M.; Rubin, G. M.;
908 Sherlock, G., Gene ontology: tool for the unification of biology. The Gene Ontology
909 Consortium. *Nat Genet* **2000**, *25* (1), 25-9.
- 910 40. Huang da, W.; Sherman, B. T.; Lempicki, R. A., Systematic and integrative analysis of
911 large gene lists using DAVID bioinformatics resources. *Nat Protoc* **2009**, *4* (1), 44-57.
- 912 41. Lew, J. M.; Kapopoulou, A.; Jones, L. M.; Cole, S. T., TubercuList--10 years after.
913 *Tuberculosis (Edinb)* **2011**, *91* (1), 1-7.
- 914 42. Camus, J. C.; Pryor, M. J.; Medigue, C.; Cole, S. T., Re-annotation of the genome
915 sequence of *Mycobacterium tuberculosis* H37Rv. *Microbiology* **2002**, *148* (Pt 10), 2967-73.
- 916 43. Kanehisa, M.; Goto, S., KEGG: kyoto encyclopedia of genes and genomes. *Nucleic*
917 *Acids Res* **2000**, *28* (1), 27-30.
- 918 44. de Castro, E.; Sigrist, C. J.; Gattiker, A.; Bulliard, V.; Langendijk-Genevaux, P. S.;
919 Gasteiger, E.; Bairoch, A.; Hulo, N., ScanProsite: detection of PROSITE signature matches
920 and ProRule-associated functional and structural residues in proteins. *Nucleic Acids Res* **2006**,
921 *34* (Web Server issue), W362-5.
- 922 45. Chou, M. F.; Schwartz, D., Biological sequence motif discovery using motif - x.
923 *Current Protocols in Bioinformatics* **2011**, 13.15. 1-13.15. 24.
- 924 46. Jensen, L. J.; Kuhn, M.; Stark, M.; Chaffron, S.; Creevey, C.; Muller, J.; Doerks, T.;
925 Julien, P.; Roth, A.; Simonovic, M.; Bork, P.; von Mering, C., STRING 8--a global view on
926 proteins and their functional interactions in 630 organisms. *Nucleic Acids Res* **2009**, *37*
927 (Database issue), D412-6.
- 928 47. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N. S.; Wang, J. T.; Ramage, D.; Amin,
929 N.; Schwikowski, B.; Ideker, T., Cytoscape: a software environment for integrated models of
930 biomolecular interaction networks. *Genome Res* **2003**, *13* (11), 2498-504.
- 931 48. Ma, Q.; Wood, T. K., Protein acetylation in prokaryotes increases stress resistance.
932 *Biochem Biophys Res Commun* **2011**, *410* (4), 846-51.
- 933 49. Xie, L.; Liu, W.; Li, Q.; Chen, S.; Xu, M.; Huang, Q.; Zeng, J.; Zhou, M.; Xie, J., First
934 succinyl-proteome profiling of extensively drug-resistant *Mycobacterium tuberculosis*
935 revealed involvement of succinylation in cellular physiology. *J Proteome Res* **2015**, *14* (1),
936 107-19.
- 937 50. Fortuin, S.; Tomazella, G. G.; Nagaraj, N.; Sampson, S. L.; Gey van Pittius, N. C.;
938 Soares, N. C.; Wiker, H. G.; de Souza, G. A.; Warren, R. M., Phosphoproteomics analysis of
939 a clinical *Mycobacterium tuberculosis* Beijing isolate: expanding the mycobacterial
940 phosphoproteome catalog. *Front Microbiol* **2015**, *6*, 6.
- 941 51. Saito, K.; Yokoyama, H.; Noji, M.; Murakoshi, I., Molecular cloning and
942 characterization of a plant serine acetyltransferase playing a regulatory role in cysteine
943 biosynthesis from watermelon. *J Biol Chem* **1995**, *270* (27), 16321-6.
- 944 52. Saito, K.; Yamazoe, Y.; Kamataki, T.; Kato, R., Mechanism of activation of proximate
945 mutagens in Ames' tester strains: The acetyl-CoA dependent enzyme in *Salmonella*

946 typhimurium TA98 deficient in TA981, 8-DNP6 catalyzes DNA-binding as the cause of
947 mutagenicity. *Biochemical and biophysical research communications* **1983**, *116* (1), 141-147.
948 53. Mukherjee, S.; Hao, Y. H.; Orth, K., A newly discovered post-translational
949 modification--the acetylation of serine and threonine residues. *Trends Biochem Sci* **2007**, *32*
950 (5), 210-6.
951 54. Holliday, G. L.; Mitchell, J. B.; Thornton, J. M., Understanding the functional roles of
952 amino acid residues in enzyme catalysis. *J Mol Biol* **2009**, *390* (3), 560-77.
953 55. Bartlett, G. J.; Porter, C. T.; Borkakoti, N.; Thornton, J. M., Analysis of catalytic
954 residues in enzyme active sites. *J Mol Biol* **2002**, *324* (1), 105-21.
955 56. Thao, S.; Escalante-Semerena, J. C., Control of protein function by reversible
956 Nvarepsilon-lysine acetylation in bacteria. *Curr Opin Microbiol* **2011**, *14* (2), 200-4.
957 57. Zhang, T.; Wang, S.; Lin, Y.; Xu, W.; Ye, D.; Xiong, Y.; Zhao, S.; Guan, K. L.,
958 Acetylation negatively regulates glycogen phosphorylase by recruiting protein phosphatase 1.
959 *Cell Metab* **2012**, *15* (1), 75-87.
960 58. Glozak, M. A.; Sengupta, N.; Zhang, X.; Seto, E., Acetylation and deacetylation of
961 non-histone proteins. *Gene* **2005**, *363*, 15-23.
962 59. Gu, W.; Roeder, R. G., Activation of p53 sequence-specific DNA binding by
963 acetylation of the p53 C-terminal domain. *Cell* **1997**, *90* (4), 595-606.
964 60. Thao, S.; Chen, C.-S.; Zhu, H.; Escalante-Semerena, J. C., Nε- lysine acetylation of a
965 bacterial transcription factor inhibits its DNA-binding activity. *PLoS one* **2010**, *5* (12), e15123.
966 61. Howe, F. S.; Boubriak, I.; Sale, M. J.; Nair, A.; Clynes, D.; Grijzenhout, A.; Murray,
967 S. C.; Woloszczuk, R.; Mellor, J., Lysine acetylation controls local protein conformation by
968 influencing proline isomerization. *Mol Cell* **2014**, *55* (5), 733-44.
969 62. Li, T.; Diner, B. A.; Chen, J.; Cristea, I. M., Acetylation modulates cellular
970 distribution and DNA sensing ability of interferon-inducible protein IFI16. *Proc Natl Acad*
971 *Sci U S A* **2012**, *109* (26), 10558-63.
972 63. Ishfaq, M.; Maeta, K.; Maeda, S.; Natsume, T.; Ito, A.; Yoshida, M., Acetylation
973 regulates subcellular localization of eukaryotic translation initiation factor 5A (eIF5A). *FEBS*
974 *Lett* **2012**, *586* (19), 3236-41.
975 64. Shaw, B. F.; Schneider, G. F.; Bilgicer, B.; Kaufman, G. K.; Neveu, J. M.; Lane, W.
976 S.; Whitelegge, J. P.; Whitesides, G. M., Lysine acetylation can generate highly charged
977 enzymes with increased resistance toward irreversible inactivation. *Protein Science* **2008**, *17*
978 (8), 1446-1455.
979 65. Sakai, H., Mutagenesis of the active site lysine 221 of the pyruvate kinase from
980 *Bacillus stearothermophilus*. *J Biochem* **2005**, *137* (2), 141-5.
981 66. Pan, J.; Ye, Z.; Cheng, Z.; Peng, X.; Wen, L.; Zhao, F., Systematic analysis of the
982 lysine acetylome in *Vibrio parahemolyticus*. *J Proteome Res* **2014**, *13* (7), 3294-302.
983 67. Pan, J.; Chen, R.; Li, C.; Li, W.; Ye, Z., Global Analysis of Protein Lysine
984 Succinylation Profiles and Their Overlap with Lysine Acetylation in the Marine Bacterium
985 *Vibrio parahemolyticus*. *J Proteome Res* **2015**, *14* (10), 4309-18.
986 68. Berndsen, C. E.; Denu, J. M., Catalysis and substrate selection by histone/protein
987 lysine acetyltransferases. *Curr Opin Struct Biol* **2008**, *18* (6), 682-9.
988 69. Wang, Q.; Zhang, Y.; Yang, C.; Xiong, H.; Lin, Y.; Yao, J.; Li, H.; Xie, L.; Zhao, W.;
989 Yao, Y.; Ning, Z. B.; Zeng, R.; Xiong, Y.; Guan, K. L.; Zhao, S.; Zhao, G. P., Acetylation of
990 metabolic enzymes coordinates carbon source utilization and metabolic flux. *Science* **2010**,
991 *327* (5968), 1004-7.
992 70. Guan, K. L.; Xiong, Y., Regulation of intermediary metabolism by protein acetylation.
993 *Trends Biochem Sci* **2011**, *36* (2), 108-16.
994 71. Zhao, S.; Xu, W.; Jiang, W.; Yu, W.; Lin, Y.; Zhang, T.; Yao, J.; Zhou, L.; Zeng, Y.;
995 Li, H.; Li, Y.; Shi, J.; An, W.; Hancock, S. M.; He, F.; Qin, L.; Chin, J.; Yang, P.; Chen, X.;

996 Lei, Q.; Xiong, Y.; Guan, K. L., Regulation of cellular metabolism by protein lysine
997 acetylation. *Science* **2010**, 327 (5968), 1000-4.

998 72. McKinney, J. D.; Honer zu Bentrup, K.; Munoz-Elias, E. J.; Miczak, A.; Chen, B.;
999 Chan, W. T.; Swenson, D.; Sacchettini, J. C.; Jacobs, W. R., Jr.; Russell, D. G., Persistence of
1000 *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme
1001 isocitrate lyase. *Nature* **2000**, 406 (6797), 735-8.

1002 73. Zu Bentrup, K. H.; Miczak, A.; Swenson, D. L.; Russell, D. G., Characterization of
1003 Activity and Expression of Isocitrate Lyase in *Mycobacterium avium* and *Mycobacterium*
1004 *tuberculosis*. *Journal of bacteriology* **1999**, 181 (23), 7161-7167.

1005 74. Munoz-Elias, E. J.; McKinney, J. D., *Mycobacterium tuberculosis* isocitrate lyases 1
1006 and 2 are jointly required for in vivo growth and virulence. *Nat Med* **2005**, 11 (6), 638-44.

1007 75. Rehman, A.; Mcfadden, B. A., The Consequences of Replacing Histidine 356 in
1008 Isocitrate Lyase from *Escherichia coli*. *Archives of biochemistry and biophysics* **1996**, 336 (2),
1009 309-315.

1010 76. Kinhikar, A. G.; Vargas, D.; Li, H.; Mahaffey, S. B.; Hinds, L.; Belisle, J. T.; Laal, S.,
1011 *Mycobacterium tuberculosis* malate synthase is a laminin - binding adhesin. *Molecular*
1012 *microbiology* **2006**, 60 (4), 999-1013.

1013 77. Shi, L.; Tu, B. P., Protein acetylation as a means to regulate protein function in tune
1014 with metabolic state. Portland Press Limited: 2014.

1015 78. Wayne, L. G.; Lin, K. Y., Glyoxylate metabolism and adaptation of *Mycobacterium*
1016 *tuberculosis* to survival under anaerobic conditions. *Infect Immun* **1982**, 37 (3), 1042-9.

1017 79. Dunn, M. F.; Ramirez-Trujillo, J. A.; Hernandez-Lucas, I., Major roles of isocitrate
1018 lyase and malate synthase in bacterial and fungal pathogenesis. *Microbiology* **2009**, 155 (Pt
1019 10), 3166-75.

1020 80. Lorenz, M. C.; Fink, G. R., Life and death in a macrophage: role of the glyoxylate
1021 cycle in virulence. *Eukaryot Cell* **2002**, 1 (5), 657-62.

1022 81. Guenin-Mace, L.; Simeone, R.; Demangel, C., Lipids of pathogenic *Mycobacteria*:
1023 contributions to virulence and host immune suppression. *Transbound Emerg Dis* **2009**, 56 (6-
1024 7), 255-68.

1025 82. Zhou, Y.; Chen, T.; Zhou, L.; Fleming, J.; Deng, J.; Wang, X.; Wang, L.; Wang, Y.;
1026 Zhang, X.; Wei, W.; Bi, L., Discovery and characterization of Ku acetylation in
1027 *Mycobacterium smegmatis*. *FEMS Microbiol Lett* **2015**, 362 (6).

1028 83. Zhang, Q.; Zhou, A.; Li, S.; Ni, J.; Tao, J.; Lu, J.; Wan, B.; Li, S.; Zhang, J.; Zhao, S.,
1029 Reversible lysine acetylation is involved in DNA replication initiation by regulating activities
1030 of initiator DnaA in *Escherichia coli*. *Scientific reports* **2016**, 6, 30837.

1031 84. Smith, T.; Wolff, K. A.; Nguyen, L., Molecular biology of drug resistance in
1032 *Mycobacterium tuberculosis*. In *Pathogenesis of Mycobacterium tuberculosis and its*
1033 *Interaction with the Host Organism*, Springer: 2012; pp 53-80.

1034 85. Ng, V. H.; Cox, J. S.; Sousa, A. O.; MacMicking, J. D.; McKinney, J. D., Role of
1035 KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative
1036 burst. *Mol Microbiol* **2004**, 52 (5), 1291-302.

1037 86. Cohen, T.; Becerra, M. C.; Murray, M. B., Isoniazid resistance and the future of drug-
1038 resistant tuberculosis. *Microb Drug Resist* **2004**, 10 (4), 280-5.

1039 87. Gotoh, Y.; Eguchi, Y.; Watanabe, T.; Okamoto, S.; Doi, A.; Utsumi, R., Two-
1040 component signal transduction as potential drug targets in pathogenic bacteria. *Curr Opin*
1041 *Microbiol* **2010**, 13 (2), 232-9.

1042 88. Pristic, S.; Husson, R. N., *Mycobacterium tuberculosis* Serine/Threonine Protein
1043 Kinases. *Microbiol Spectr* **2014**, 2 (5).

1044 89. Jhingan, G. D.; Kumari, S.; Jamwal, S. V.; Kalam, H.; Arora, D.; Jain, N.; Kumaar, L.
1045 K.; Samal, A.; Rao, K. V.; Kumar, D.; Nandicoori, V. K., Comparative Proteomic Analyses

1046 of Avirulent, Virulent, and Clinical Strains of Mycobacterium tuberculosis Identify Strain-
1047 specific Patterns. *J Biol Chem* **2016**, *291* (27), 14257-73.

1048 90. Mukherjee, P.; Sureka, K.; Datta, P.; Hossain, T.; Barik, S.; Das, K. P.; Kundu, M.;
1049 Basu, J., Novel role of Wag31 in protection of mycobacteria under oxidative stress. *Mol*
1050 *Microbiol* **2009**, *73* (1), 103-19.

1051 91. Kang, C. M.; Nyayapathy, S.; Lee, J. Y.; Suh, J. W.; Husson, R. N., Wag31, a
1052 homologue of the cell division protein DivIVA, regulates growth, morphology and polar cell
1053 wall synthesis in mycobacteria. *Microbiology* **2008**, *154* (Pt 3), 725-35.

1054 92. Unal, C. M.; Steinert, M., Microbial peptidyl-prolyl cis/trans isomerases (PPIases):
1055 virulence factors and potential alternative drug targets. *Microbiol Mol Biol Rev* **2014**, *78* (3),
1056 544-71.

1057 93. Munshi, T.; Gupta, A.; Evangelopoulos, D.; Guzman, J. D.; Gibbons, S.; Keep, N. H.;
1058 Bhakta, S., Characterisation of ATP-dependent Mur ligases involved in the biogenesis of cell
1059 wall peptidoglycan in Mycobacterium tuberculosis. *PLoS One* **2013**, *8* (3), e60143.

1060 94. Tseng, S. T.; Tai, C. H.; Li, C. R.; Lin, C. F.; Shi, Z. Y., The mutations of katG and
1061 inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan. *J Microbiol*
1062 *Immunol Infect* **2015**, *48* (3), 249-55.

1063 95. Ramaswamy, S. V.; Reich, R.; Dou, S. J.; Jasperse, L.; Pan, X.; Wanger, A.; Quitugua,
1064 T.; Graviss, E. A., Single nucleotide polymorphisms in genes associated with isoniazid
1065 resistance in Mycobacterium tuberculosis. *Antimicrob Agents Chemother* **2003**, *47* (4), 1241-
1066 50.

1067 96. Chien, J. Y.; Chiu, W. Y.; Chien, S. T.; Chiang, C. J.; Yu, C. J.; Hsueh, P. R.,
1068 Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant
1069 Mycobacterium tuberculosis Isolates. *Antimicrob Agents Chemother* **2016**, *60* (4), 2090-6.

1070 97. Wang, J. Y.; Lee, L. N.; Lai, H. C.; Wang, S. K.; Jan, I. S.; Yu, C. J.; Hsueh, P. R.;
1071 Yang, P. C., Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated
1072 genetic mutations and relationship to antimicrobial exposure. *J Antimicrob Chemother* **2007**,
1073 *59* (5), 860-5.

1074 98. Pitaksajjakul, P.; Wongwit, W.; Punprasit, W.; Eampokalap, B.; Peacock, S.;
1075 Ramasoota, P., Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant
1076 Mycobacterium tuberculosis from TB patients in Thailand. *Southeast Asian J Trop Med*
1077 *Public Health* **2005**, *36 Suppl 4*, 228-37.

1078 99. Chen, W.; Biswas, T.; Porter, V. R.; Tsodikov, O. V.; Garneau-Tsodikova, S., Unusual
1079 regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB. *Proc Natl*
1080 *Acad Sci U S A* **2011**, *108* (24), 9804-8.

1081 100. Tsodikov, O. V.; Green, K. D.; Garneau-Tsodikova, S., A random sequential
1082 mechanism of aminoglycoside acetylation by Mycobacterium tuberculosis Eis protein. *PLoS*
1083 *One* **2014**, *9* (4), e92370.

1084 101. Yimer, S. A.; Norheim, G.; Namouchi, A.; Zegeye, E. D.; Kinander, W.; Tonjum, T.;
1085 Bekele, S.; Mannsaker, T.; Bjune, G.; Aseffa, A.; Holm-Hansen, C., Mycobacterium
1086 tuberculosis lineage 7 strains are associated with prolonged patient delay in seeking treatment
1087 for pulmonary tuberculosis in Amhara Region, Ethiopia. *J Clin Microbiol* **2015**, *53* (4), 1301-
1088 9.

1089 102. Yimer, S. A.; Birhanu, A. G.; Kalayou, S.; Riaz, T.; Zegeye, E. D.; Beyene, G. T.;
1090 Holm-Hansen, C.; Norheim, G.; Abebe, M.; Aseffa, A.; Tonjum, T., Comparative Proteomic
1091 Analysis of Mycobacterium tuberculosis Lineage 7 and Lineage 4 Strains Reveals
1092 Differentially Abundant Proteins Linked to Slow Growth and Virulence. *Front Microbiol*
1093 **2017**, *8*, 795.

1094 103. Eisenreich, W.; Dandekar, T.; Heesemann, J.; Goebel, W., Carbon metabolism of
1095 intracellular bacterial pathogens and possible links to virulence. *Nat Rev Microbiol* **2010**, *8*
1096 (6), 401-12.

1097 104. Munoz-Elias, E. J.; McKinney, J. D., Carbon metabolism of intracellular bacteria. *Cell*
1098 *Microbiol* **2006**, *8* (1), 10-22.

1099 105. Zhang, X.; Ji, R.; Liao, X.; Deng, L. Y.; Castellero, E.; Givens, R.; George, I.; Schulze,
1100 P. C., Lysine Acetylation of Pyruvate Dehydrogenase Reduces Enzymatic Activity and
1101 Contributes to Impaired Substrate Metabolism in the Failing Myocardium. *Am Heart Assoc*:
1102 2014.

1103 106. Ozden, O.; Park, S. H.; Wagner, B. A.; Song, H. Y.; Zhu, Y.; Vassilopoulos, A.; Jung,
1104 B.; Buettner, G. R.; Gius, D., SIRT3 deacetylates and increases pyruvate dehydrogenase
1105 activity in cancer cells. *Free Radic Biol Med* **2014**, *76*, 163-172.

1106 107. Li, R.; Gu, J.; Chen, P.; Zhang, Z.; Deng, J.; Zhang, X., Purification and
1107 characterization of the acetyl-CoA synthetase from *Mycobacterium tuberculosis*. *Acta*
1108 *Biochim Biophys Sin (Shanghai)* **2011**, *43* (11), 891-9.

1109 108. McKinney, J. D.; zu Bentrup, K. H.; Muñoz-Elías, E. J.; Miczak, A., Persistence of
1110 *Mycobacterium tuberculosis* in macrophages and mice requires the glyoxylate shunt enzyme
1111 isocitrate lyase. *Nature* **2000**, *406* (6797), 735.

1112 109. Shi, L.; Sohaskey, C. D.; Pfeiffer, C.; Datta, P.; Parks, M.; McFadden, J.; North, R. J.;
1113 Gennaro, M. L., Carbon flux rerouting during *Mycobacterium tuberculosis* growth arrest. *Mol*
1114 *Microbiol* **2010**, *78* (5), 1199-215.

1115 110. Wolfe, A. J., The acetate switch. *Microbiol Mol Biol Rev* **2005**, *69* (1), 12-50.

1116 111. Contiero, J.; Beatty, C.; Kumari, S.; DeSanti, C. L.; Strohl, W. R.; Wolfe, A., Effects
1117 of mutations in acetate metabolism on high-cell-density growth of *Escherichia coli*. *Journal of*
1118 *Industrial Microbiology & Biotechnology* **2000**, *24* (6), 421-430.

1119 112. Billig, S.; Schneefeld, M.; Huber, C.; Grassl, G. A.; Eisenreich, W.; Bange, F.-C.,
1120 Lactate oxidation facilitates growth of *Mycobacterium tuberculosis* in human macrophages.
1121 *Scientific reports* **2017**, *7* (1), 6484.

1122 113. Banerjee, R.; Vats, P.; Dahale, S.; Kasibhatla, S. M.; Joshi, R., Comparative genomics
1123 of cell envelope components in mycobacteria. *PLoS One* **2011**, *6* (5), e19280.

1124 114. Daniel, J.; Sirakova, T.; Kolattukudy, P., An acyl-CoA synthetase in *Mycobacterium*
1125 *tuberculosis* involved in triacylglycerol accumulation during dormancy. *PLoS One* **2014**, *9*
1126 (12), e114877.

1127 115. Chen, J. M., Mycosins of the *Mycobacterium* Type VII ESX Secretion System: the
1128 Glue That Holds the Party Together. *MBio* **2016**, *7* (6), e02062-16.

1129 116. Peirs, P.; Lefevre, P.; Boarbi, S.; Wang, X.-M.; Denis, O.; Braibant, M.; Pethe, K.;
1130 Locht, C.; Huygen, K., *Mycobacterium tuberculosis* with disruption in genes encoding the
1131 phosphate binding proteins PstS1 and PstS2 is deficient in phosphate uptake and demonstrates
1132 reduced in vivo virulence. *Infection and immunity* **2005**, *73* (3), 1898-1902.

1133 117. Colangeli, R.; Helb, D.; Sridharan, S.; Sun, J.; Varma-Basil, M.; Hazbon, M. H.;
1134 Harbacheuski, R.; Megjugorac, N. J.; Jacobs, W. R., Jr.; Holzenburg, A.; Sacchettini, J. C.;
1135 Alland, D., The *Mycobacterium tuberculosis* *iniA* gene is essential for activity of an efflux
1136 pump that confers drug tolerance to both isoniazid and ethambutol. *Mol Microbiol* **2005**, *55*
1137 (6), 1829-40.

1138 118. Zhang, F.; Xie, J. P., Mammalian cell entry gene family of *Mycobacterium*
1139 *tuberculosis*. *Mol Cell Biochem* **2011**, *352* (1-2), 1-10.

1140 119. Vizcaíno, J. A.; Csordas, A.; del-Toro, N.; Dianes, J. A.; Griss, J.; Lavidas, I.; Mayer,
1141 G.; Perez-Riverol, Y.; Reisinger, F.; Ternent, T., 2016 update of the PRIDE database and its
1142 related tools. *Nucleic acids research* **2016**, *44* (D1), D447-D456.

